Observational Trial of the Updated Inserter for the Travoprost Intracameral Implant 75mcg

Clinical In-use Observational Trial to Evaluate the Updated Inserter for the Travoprost Intracameral Implant 75 mcg

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07400926

Acronym

TRIO

Enrollment

Registered

2026-02-10

Start date

2025-12-17

Completion date

2026-07-01

Last updated

2026-02-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Open Angle Glaucoma (OAG), Ocular Hypertension (OH)

Keywords

Glaucoma, Ocular Hypertension

Brief summary

Clinical in-use observational trial to evaluate the updated inserter for the Travoprost Intracameral implant using the updated inserter (Model G2-TRIO)

Detailed description

The objective of this study is to evaluate the administration of the Travoprost intracameral implant using the updated inserter (Model G2-TRIO)

Interventions

COMBINATION_PRODUCTTravoprost

Travoprost intracameral implant, 75mcg administered using the sterile, single-dose updated inserter (Model G2-TRIO)

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Diagnosis of Open-angle glaucoma * 18 years of age or older

Exclusion criteria

* Subject who is breast-feeding or pregnant

Design outcomes

Primary

Measure	Time frame	Description
Successful implantation	1 day	Proportion of subjects for which Investigator was able to successfully follow the Instructions For Use/Prescribing Information and correctly administer the model G2-TRIO travoprost intracameral implant 75mcg with the updated inserter

Countries

United States

Contacts

CONTACTStudy Director

ClinicalResearch@glaukos.com949-739-8749

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 28, 2026